Literature DB >> 17318340

Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.

Liselotte P van Hest1, Mariëlle W G Ruijs, Anja Wagner, Conny A van der Meer, Senno Verhoef, Laura J van't Veer, Hanne Meijers-Heijboer.   

Abstract

Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited cancer predisposition syndrome characterized by a combination of tumors including sarcoma, breast cancer, brain tumors, adrenocortical carcinoma and leukemia. Germline mutations in the tumor suppressor gene TP53 are associated with LFS. We present a family with LFS in which initially a novel germline TP53 intron 5 splice site mutation was found. A second germline TP53 mutation, the exon 7 Asn235Ser (704A-->G) mutation, was detected in this family through pre-symptomatic DNA testing. This latter mutation has been reported repeatedly in the literature as a pathogenic mutation involved in LFS. We provide evidence for pathogenicity of the novel intron 5 splice site mutation, whereas this evidence is lacking for the exon 7 Asn235Ser (704A-->G) mutation. Our findings emphasize the importance of performing additional tests in case of germline sequence variants with uncertain functional effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318340     DOI: 10.1007/s10689-006-9115-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  20 in total

1.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

Review 2.  On the expression of the p53 protein in human cancer.

Authors:  D P Lane
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

3.  Three germline mutations in the TP53 gene.

Authors:  R S Cornelis; M van Vliet; M J van de Vijver; H F Vasen; P A Voute; B Top; P M Khan; P Devilee; C J Cornelisse
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

Review 4.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 5.  The UMD-p53 database: new mutations and analysis tools.

Authors:  Christophe Béroud; Thierry Soussi
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information.

Authors:  S M Hebsgaard; P G Korning; N Tolstrup; J Engelbrecht; P Rouzé; S Brunak
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

8.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

9.  A subset of p53-deficient embryos exhibit exencephaly.

Authors:  V P Sah; L D Attardi; G J Mulligan; B O Williams; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

10.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  6 in total

1.  One man, one disease?

Authors:  Frankie Wai Tsoi Cheng; K F To; V Lee; M M K Shing; W K Leung; C K Li
Journal:  BMJ Case Rep       Date:  2009-04-28

2.  MicroRNA binding site polymorphisms as biomarkers of cancer risk.

Authors:  Cory Pelletier; Joanne B Weidhaas
Journal:  Expert Rev Mol Diagn       Date:  2010-09       Impact factor: 5.225

3.  Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.

Authors:  Matthew B Yurgelun; Serena Masciari; Victoria A Joshi; Rowena C Mercado; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins; Daniel D Buchanan; Polly A Newcomb; John D Potter; Robert W Haile; Raju Kucherlapati; Sapna Syngal
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

4.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

5.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

6.  Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients.

Authors:  Ali A Alshatwi; Gowhar Shafi; Tarique N Hasan; Naveed Ahmed Syed; Amal A Al-Hazzani; Mohammed A Alsaif; Abdulaziz A Alsaif
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.